Company profile: Amend Surgical
1.1 - Company Overview
Company description
- Provider of natural and synthetic bone graft substitutes and orthobiologic solutions to enhance bone healing. Portfolio includes NanoFUSE Bioactive Matrix, a bone void filler combining bioactive glass and demineralized allograft for orthopedic and spinal fusion; Amend Tissue Tape, a non-resorbable hydrogel surgical glue for protecting oral wounds; and Tissure, a degradable hydrogel/chitosan adhesive for suture-less nerve repair to reconnect peripheral nerves.
Products and services
- NanoFUSE Bioactive Matrix: A bioactive bone void filler implant combining bioactive glass and demineralized allograft bone to aid orthopedic and spinal fusion procedures by filling defects and supporting fusion
- Tissure: A degradable hydrogel and chitosan-based adhesive for suture-less nerve repair, providing barrier protection and mechanical strength to reconnect peripheral nerves during healing
- Amend Tissue Tape: A non-resorbable hydrogel and surgical glue designed to adhere to and protect wounds in the oral cavity during healing
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Amend Surgical
ChitogenX
HQ: Canada
Website
- Description: Provider of orthopedic biotechnology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ChitogenX company profile →
CoAlign
HQ: United States
Website
- Description: Provider of hydraulic expansion technology and a locking mechanism for expandable interbody implants in spine surgery. Its AccuLIF system delivers a low-profile interbody implant that expands to achieve accurate fit and placement for lower lumbar procedures; CoAlign developed and provided the first expandable interbody implant for use in these procedures.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CoAlign company profile →
DFine
HQ: United States
Website
- Description: Provider of therapeutic medical devices and therapies for managing compression fractures of the spine, offering pain relief for patients and new, promising options for physicians. Acquired by Merit Medical Systems in July 2016.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DFine company profile →
Angitia Bio
HQ: China
Website
- Description: Provider of biopharmaceutical therapeutics focused on discovery and development of innovative treatments, including AGA111, a Phase III drug candidate to enhance spinal fusion; AGA2115, a Phase I novel biologic for Osteogenesis Imperfecta with FDA Orphan Drug and Rare Pediatric Disease designations; and AGA2118, an additional pipeline program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Angitia Bio company profile →
SafeWire
HQ: United States
Website
- Description: Provider of minimally invasive surgical instruments for spine procedures. Offers the Y-Wire with a patented design to reduce guidewire-related complications such as inadvertent advancement through bone, accidental pullout, kinking, and wire migration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SafeWire company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Amend Surgical
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Amend Surgical
2.2 - Growth funds investing in similar companies to Amend Surgical
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Amend Surgical
4.2 - Public trading comparable groups for Amend Surgical
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →